Clinically low plasma and intracellular Gln concentrations and decreased mucosal glutaminase activity in Crohn’s disease patients indicated that Gln metabolism was impaired therein, from which it was hypothesized that Gln supplementation would improve the clinical manifestations of Crohn’s disease (24). This evidence concerns the gene GLS and Crohn disease.